XTX Topco Ltd Cuts Holdings in Encompass Health Corporation (NYSE:EHC)

XTX Topco Ltd cut its position in shares of Encompass Health Corporation (NYSE:EHC - Free Report) by 64.5% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,132 shares of the company's stock after selling 3,874 shares during the quarter. XTX Topco Ltd's holdings in Encompass Health were worth $216,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Colonial Trust Co SC purchased a new position in shares of Encompass Health during the fourth quarter worth approximately $29,000. Transce3nd LLC purchased a new position in shares of Encompass Health during the fourth quarter worth approximately $40,000. Arlington Trust Co LLC boosted its holdings in Encompass Health by 22.9% during the 1st quarter. Arlington Trust Co LLC now owns 671 shares of the company's stock valued at $68,000 after acquiring an additional 125 shares during the period. Johnson Financial Group Inc. purchased a new stake in Encompass Health during the 4th quarter valued at about $72,000. Finally, Mowery & Schoenfeld Wealth Management LLC purchased a new stake in Encompass Health during the 1st quarter valued at about $87,000. 97.25% of the stock is currently owned by institutional investors.

Encompass Health Stock Up 0.6%

Shares of NYSE:EHC traded up $0.70 during trading on Friday, hitting $120.35. The stock had a trading volume of 604,151 shares, compared to its average volume of 943,532. Encompass Health Corporation has a 12 month low of $87.85 and a 12 month high of $123.13. The company has a market capitalization of $12.12 billion, a PE ratio of 23.55, a PEG ratio of 2.10 and a beta of 0.86. The firm's fifty day moving average is $116.13 and its 200 day moving average is $109.56. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.76.

Encompass Health (NYSE:EHC - Get Free Report) last announced its earnings results on Monday, August 4th. The company reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.20 by $0.20. Encompass Health had a return on equity of 17.83% and a net margin of 9.22%. The firm had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.43 billion. During the same quarter in the prior year, the company earned $1.11 EPS. The business's revenue was up 12.0% compared to the same quarter last year. Analysts anticipate that Encompass Health Corporation will post 4.8 EPS for the current fiscal year.

Encompass Health Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Wednesday, October 1st will be paid a $0.19 dividend. This represents a $0.76 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Wednesday, October 1st. This is an increase from Encompass Health's previous quarterly dividend of $0.17. Encompass Health's dividend payout ratio (DPR) is currently 14.87%.

Insider Buying and Selling at Encompass Health

In related news, CEO Mark J. Tarr sold 118,384 shares of the company's stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $121.53, for a total value of $14,387,207.52. Following the sale, the chief executive officer owned 527,070 shares in the company, valued at $64,054,817.10. This represents a 18.34% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 2.00% of the stock is owned by insiders.

Analyst Ratings Changes

Several brokerages recently weighed in on EHC. KeyCorp increased their target price on Encompass Health from $122.00 to $135.00 and gave the company an "overweight" rating in a report on Tuesday, May 27th. UBS Group increased their target price on Encompass Health from $130.00 to $140.00 and gave the company a "buy" rating in a report on Wednesday, August 6th. Barclays increased their target price on Encompass Health from $118.00 to $129.00 and gave the company an "overweight" rating in a report on Friday, April 25th. Truist Financial set a $140.00 price target on Encompass Health and gave the company a "buy" rating in a research report on Thursday. Finally, Royal Bank Of Canada upped their price target on Encompass Health from $110.00 to $125.00 and gave the company an "outperform" rating in a research report on Monday, April 28th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Encompass Health presently has a consensus rating of "Buy" and a consensus target price of $134.00.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.